Healthcare & Medical
Category / Healthcare & Medical
: A new model from the Karl Landsteiner University of Health Sciences provides the basis for optimal positioning of orthopaedic screws.
...
HONG KONG: Key Highlights
- Clinical trial to evaluate the safety and efficacy of YK012 in primary membranous nephropathy
- Globally, this is the first bispecific CD19-directed CD3 T cell engager immunothe ...
Singapore / Bangkok,: - Offer price of S$0.25 per share is at an attractive premium of 61.3% over the last traded price being 9 May 2025 and the 12-month volume-weighted average price
- The Partial offer provides Cordlife ...
Houston, TX,: - Results from the first patient cohort (N=5) of an open-label proof of concept academic study with low-dose IL-2 and CTLA4-Ig demonstrated a rapid and durable statistically significant increase in th ...
TOKYO: Names Bob White Representative Executive Officer, President, Chief Executive Officer and a new Director candidate ...
HONG KONG: HONG KONG, Apr 24, 2025 - (ACN Newswire) – HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapi ...
SHANGHAI: SHANGHAI, Apr 22, 2025 - (ACN Newswire) – Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufactu ...
HONG KONG: - Continuoued to consolidate The leading position of nuclear medicine and facilitated the development of nuclear medical equipment as a new engine
...
HONG KONG: - HighTide Therapeutics Announces HTD1801 Meets the Primary Endpoints in Two Phase 3 Clinical Trials in Patients with Type 2 Diabetes Mellitus
...
Singapore: Awards highlight Avantor's commitment to the Biopharma industry
SINGAPORE, Mar 31, 2025 - (ACN Newswire) - Avantor Inc., a leading global provider of mission-critical products and services to ...
BETHESDA, MD,: Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson's Disease
...
HONG KONG: HONG KONG, Mar 7, 2025 - (ACN Newswire) - Everest Medicines' stock (1952.HK) surged today, opening higher and maintaining strong momentum throughout the trading day. By market close, the stock ha ...
